Keyphrases
Neurofibromatosis Type I
100%
Neurofibromatosis Type 1 (NF-1)
98%
Plexiform Neurofibroma
91%
Pediatric Patients
88%
Wilms Tumor
75%
Neuroblastoma
56%
Tumor
50%
High Risk
42%
Clinical Management
37%
Single-center Experience
35%
Next-generation Sequencing
35%
Graft-versus-host Disease (GvHD)
26%
Umbilical Cord Blood Transplantation
26%
MEK Inhibitor (MEKi)
26%
Children with Cancer
26%
Chemotherapy
25%
High-risk Neuroblastoma
25%
Clinical Trials
24%
Quality of Life
22%
Oncology
21%
Childrens
21%
Treatment Decisions
21%
Pediatric
20%
Neurofibromatosis
20%
Neoplasms
20%
Phase II Trial
19%
Cabozantinib
19%
Clinical Trial Development
17%
Commercially Available
17%
Clinical Performance
17%
Proximal Hypospadias
17%
Tumor Burden
17%
Imatinib Mesylate
17%
Giant Cell Tumor
17%
Etiology
17%
Inframammary
17%
Non-invasive Diagnosis
17%
Infection Diagnosis
17%
Metagenomic Next-generation Sequencing (mNGS)
17%
Metastatic Osteosarcoma
17%
Mouse Model
17%
Peripheral Nervous System Tumours
17%
Clinical Trial Management
17%
Entrectinib
17%
Experimental Therapeutics
17%
Diagnostic Test
17%
Mucocutaneous Exposure
17%
Solid Organ Transplantation
17%
Solitary Neurofibroma
17%
KAP1
17%
Medicine and Dentistry
Plexiform Neurofibroma
83%
Neurofibromatosis Type I
80%
Neoplasm
74%
Pediatrics Patient
68%
Wilms' Tumor
57%
Ganglioneuroblastoma
56%
Pediatrics
43%
Clinical Management
38%
Clinical Trial
38%
Neurofibromatosis
35%
Next Generation Sequencing
35%
Quality of Life
28%
MEK Inhibitor
26%
Side Effect
24%
Infection
22%
Pediatric Cancer
22%
Skin Toxicity
22%
Stem Cell Transplant
20%
Drive
20%
Oncology
20%
Transplantation
20%
Cabozantinib
19%
Adverse Event
19%
Hemodialysis
17%
Irinotecan
17%
Giant Cell Tumor
17%
Genetic Screening
17%
Hypospadias
17%
Bloodstream Infection
17%
Solid Organ Transplantation
17%
Reading Frame
17%
Sorafenib
17%
Graft Versus Host Reaction
17%
Papillary Thyroid Cancer
17%
Consolidation Chemotherapy
17%
Malignant Transformation
17%
Renal Failure
17%
Late Effect
17%
Entrectinib
17%
Counseling
17%
Skin Manifestation
17%
Systematic Review
17%
Cancer Therapy
17%
Fibrosarcoma
17%
Malignant Neoplasm
17%
Congenital Central Hypoventilation Syndrome
17%
Neurocristopathy
17%
Somatics
17%
Rhabdomyosarcoma
17%
Mucosal Surface
17%
